GlassScriptPhysician profile
Venkata B Kantamneni
NPI 1851377527
$1,635.79
in general payments reported to CMS, 2019-2025
12 companies · $255 in 2025
The $255 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $273 · 2021: $306 · 2022: $367 · 2023: $93.34 · 2024: $204 · 2025: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $552.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $985.02 | 2020-2025 | |
| Braintree Laboratories, INC. | $141.45 | 2020-2022 | |
| Covidien LP | $124.47 | 2019 | |
| Pfizer INC. | $93.95 | 2020-2022 | |
| Redhill Biopharma INC. | $75.02 | 2020 | |
| Ferring Pharmaceuticals INC. | $44.40 | 2020-2025 | Rebyota |
| Johnson & Johnson Surgical Vision, INC. | $44.04 | 2020-2023 | Tecnis Simplicity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.65 | 2020-2021 | |
| Janssen Biotech, INC. | $31.66 | 2021 | |
| Madrigal Pharmaceuticals | $26.82 | 2025 | Rezdiffra |
| Allergan, INC. | $13.92 | 2020 | |
| Boston Scientific Corporation | $13.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Venkata Kantamneni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.